LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• LeMaitre Vascular, Inc. (NASDAQ:LMAT) has received a consensus rating of "Moderate Buy" from six analysts, with an average 12-month price target of $97.60.
• Insider activity showed a significant sale, with Director Bridget A. Ross selling 2,500 shares and Director David B. Roberts selling 10,815 shares, representing notable decreases in their stakes in the company.
• The company recently reported earnings, exceeding expectations with $0.60 EPS and a revenue of $63.15 million, indicating a 15% increase year-over-year.

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) has been given a consensus rating of "Moderate Buy" by the six analysts that are covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $97.60.

A number of equities research analysts have recently issued reports on LMAT shares. Weiss Ratings reaffirmed a "buy (b-)" rating on shares of LeMaitre Vascular in a report on Saturday, September 27th. Barrington Research reaffirmed an "outperform" rating and issued a $95.00 target price on shares of LeMaitre Vascular in a report on Tuesday, September 23rd. Finally, Cantor Fitzgerald upped their target price on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th.

Insider Activity

In other LeMaitre Vascular news, Director Bridget A. Ross sold 2,500 shares of the stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $94.00, for a total value of $235,000.00. Following the transaction, the director directly owned 2,916 shares of the company's stock, valued at $274,104. This represents a 46.16% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David B. Roberts sold 10,815 shares of the stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $92.39, for a total transaction of $999,197.85. Following the completion of the transaction, the director directly owned 17,976 shares in the company, valued at approximately $1,660,802.64. This represents a 37.56% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 120,815 shares of company stock valued at $11,280,206 in the last 90 days. 9.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of LMAT. GAMMA Investing LLC raised its holdings in LeMaitre Vascular by 7,486.5% in the 1st quarter. GAMMA Investing LLC now owns 53,864 shares of the medical instruments supplier's stock valued at $4,519,000 after acquiring an additional 53,154 shares during the period. NBC Securities Inc. bought a new position in LeMaitre Vascular in the 1st quarter valued at about $36,000. Vest Financial LLC bought a new position in LeMaitre Vascular in the 1st quarter valued at about $1,470,000. Compass Planning Associates Inc raised its holdings in LeMaitre Vascular by 91.4% in the 1st quarter. Compass Planning Associates Inc now owns 11,776 shares of the medical instruments supplier's stock valued at $988,000 after acquiring an additional 5,623 shares during the period. Finally, Wesbanco Bank Inc. bought a new position in LeMaitre Vascular in the 1st quarter valued at about $470,000. 84.64% of the stock is owned by institutional investors.

LeMaitre Vascular Price Performance

Shares of NASDAQ LMAT opened at $87.85 on Friday. The firm has a market cap of $1.99 billion, a PE ratio of 42.65, a PEG ratio of 2.26 and a beta of 0.77. The company has a current ratio of 13.96, a quick ratio of 11.74 and a debt-to-equity ratio of 0.46. LeMaitre Vascular has a 1-year low of $71.42 and a 1-year high of $109.58. The company has a fifty day moving average price of $91.66 and a 200 day moving average price of $86.28.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The medical instruments supplier reported $0.60 EPS for the quarter, topping analysts' consensus estimates of $0.57 by $0.03. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The company had revenue of $63.15 million during the quarter, compared to the consensus estimate of $62.48 million. During the same period in the prior year, the business posted $0.52 EPS. The company's quarterly revenue was up 15.0% on a year-over-year basis. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. Research analysts predict that LeMaitre Vascular will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, September 4th. Stockholders of record on Thursday, August 21st were issued a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend was Thursday, August 21st. LeMaitre Vascular's dividend payout ratio is presently 38.83%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.